External Seminar: “Novel advances in targeting the DNA damage response in the Clinic”
This seminar will take place in person only.
Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Centre. He is a Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is Vice President and Head of Clinical Development in the Therapeutics Discovery Division, a drug discovery biopharmaceutical division where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Khalifa Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes.

Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR, PARP1, WEE1, POLQ, USP1, PKMYT1, PARG, CHK1, ATM and DNA-PK inhibitors, next generation CDK2, CDK4 and CDK7-selective inhibitors, YAP/TEAD inhibitors, Werner helicase inhibitors, SMARCA2 degraders, as well as the development of novel immunotherapeutics.
Date: 10 May 2024, 12:00 (Friday, 3rd week, Trinity 2024)
Venue: Old Road Campus Research Building, Headington OX3 7DQ
Venue Details: 71A/B/C
Speaker: Professor Timothy Yap
Organising department: Department of Oncology
Organiser contact email address: adminsupport@oncology.ox.ac.uk
Host: Dr Eileen Parkes (Group Leader, Innate Tumour Immunology. Department of Oncology, University of Oxford)
Booking required?: Not required
Audience: Members of the University only
Editor: Annabelle Ziegler